文献速递前列腺癌

Prostascore模型在转移性激素敏感性前列腺癌患者中的外部验证:CHAARTED研究分析

External validation of the prostascore model in patients with metastatic hormone-sensitive prostate cancer recruited to the CHAARTED study.
PubMed 文献 · BJU Int · 2018-02-20

本研究对CHAARTED研究中702例转移性激素敏感性前列腺癌患者进行回顾性分析,外部验证Prostascore模型。结果显示Prostascore与总生存和无进展生存均显著相关(趋势P<0.001),且不同评分下治疗臂间总生存差异不同。

要点

  • Prostascore评分与转移性激素敏感性前列腺癌患者的总生存显著相关(趋势P<0.001)。
  • Prostascore评分与无进展生存也显著相关(趋势P<0.001)。
  • 不同Prostascore评分下治疗臂间总生存差异不同:评分2无显著差异(P=0.702),评分3、4、5有显著差异(P<0.05)。

核心结论

  • Prostascore可预测转移性激素敏感性前列腺癌患者的总生存和无进展生存,并可能辅助治疗决策。

研究设计与样本

  • 对CHAARTED研究(2006-2014年III期多中心研究)中前瞻性收集的数据进行回顾性分析,共702例有完整基线数据可计算Prostascore的患者纳入分析。

主要发现

  • 全队列中Prostascore与总生存趋势显著相关(P<0.001)。
  • 全队列中Prostascore与无进展生存趋势显著相关(P<0.001)。
  • 按治疗臂比较总生存,Prostascore=2时差异无统计学意义(P=0.702),Prostascore=3、4、5时差异有统计学意义(P<0.05)。
  • 癌症特异性生存的病因特异性风险比(校正治疗臂)成对比较中,除评分4与5比较外,其余比较P值均<0.01。

临床怎么用

  • Prostascore可能有助于转移性激素敏感性前列腺癌患者的预后分层和治疗决策。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To externally validate 'prostascore' in patients with metastatic hormone-sensitive prostate cancer recruited to the phase III CHAARTED study. METHODS: We conducted a retrospective analysis of the prospectively collected data from patients with metastatic hormone-sensitive prostate cancer in the CHAARTED study, a phase III multicentre study conducted between 2006 and 2014. The main outcome of the present analysis was overall survival, assessed using Kaplan-Meier analysis or log-rank testing, in the whole cohort according to different prostascores. In addition, patients with different scores were compared according to treatment arm. RESULTS: A total of 702 cases had complete baseline data, allowing calculation of prostascores and inclusion in the present analysis. Overall survival was assessed according to prostascores in the entire cohort and the P value for overall survival trend was significant (P < 0.001). Likewise, progression-free survival was assessed according to prostascores in the entire cohort and the P value for progression-free survival trend was also significant (P < 0.001). Overall survival comparisons according to treatment arm were evaluated among different prostascores. Notably, the P value for overall survival difference was not significant for a prostascore = 2 (P = 0.702), but was significant for scores of 3, 4 and 5 (P < 0.05). The cause-specific hazard ratio for cancer-specific survival (adjusted for treatment arm used) was also evaluated. The P value for pairwise comparisons between different scores was significant (P < 0.01) except for the comparison between scores 4 and 5. CONCLUSION: The present study further confirms the role of prostascore in predicting the outcomes of patients with metastatic hormone-sensitive prostate cancer and also highlights its potential role in therapeutic decision-making.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Abdel-Rahman O, Cheung WY. External validation of the prostascore model in patients with metastatic hormone-sensitive prostate cancer recruited to the CHAARTED study. BJU Int. 2018. PMID: 29359398. doi:10.1111/bju.14138

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。